These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 24117733)

  • 21. Changes in matrix metalloprotease activity and progranulin levels may contribute to the pathophysiological function of mutant leucine-rich repeat kinase 2.
    Caesar M; Felk S; Zach S; Brønstad G; Aasly JO; Gasser T; Gillardon F
    Glia; 2014 Jul; 62(7):1075-92. PubMed ID: 24652679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemical genetic approach identifies microtubule affinity-regulating kinase 1 as a leucine-rich repeat kinase 2 substrate.
    Krumova P; Reyniers L; Meyer M; Lobbestael E; Stauffer D; Gerrits B; Muller L; Hoving S; Kaupmann K; Voshol J; Fabbro D; Bauer A; Rovelli G; Taymans JM; Bouwmeester T; Baekelandt V
    FASEB J; 2015 Jul; 29(7):2980-92. PubMed ID: 25854701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigation of leucine-rich repeat kinase 2 : enzymological properties and novel assays.
    Anand VS; Reichling LJ; Lipinski K; Stochaj W; Duan W; Kelleher K; Pungaliya P; Brown EL; Reinhart PH; Somberg R; Hirst WD; Riddle SM; Braithwaite SP
    FEBS J; 2009 Jan; 276(2):466-78. PubMed ID: 19076219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition.
    Fell MJ; Mirescu C; Basu K; Cheewatrakoolpong B; DeMong DE; Ellis JM; Hyde LA; Lin Y; Markgraf CG; Mei H; Miller M; Poulet FM; Scott JD; Smith MD; Yin Z; Zhou X; Parker EM; Kennedy ME; Morrow JA
    J Pharmacol Exp Ther; 2015 Dec; 355(3):397-409. PubMed ID: 26407721
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic dissection reveals that Akt is the critical kinase downstream of LRRK2 to phosphorylate and inhibit FOXO1, and promotes neuron survival.
    Chuang CL; Lu YN; Wang HC; Chang HY
    Hum Mol Genet; 2014 Nov; 23(21):5649-58. PubMed ID: 24916379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
    Kethiri RR; Bakthavatchalam R
    Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological inhibition of LRRK2 cellular phosphorylation sites provides insight into LRRK2 biology.
    Zhao J; Hermanson SB; Carlson CB; Riddle SM; Vogel KW; Bi K; Nichols RJ
    Biochem Soc Trans; 2012 Oct; 40(5):1158-62. PubMed ID: 22988882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Leucine-rich repeat kinase 2 exacerbates neuronal cytotoxicity through phosphorylation of histone deacetylase 3 and histone deacetylation.
    Han KA; Shin WH; Jung S; Seol W; Seo H; Ko C; Chung KC
    Hum Mol Genet; 2017 Jan; 26(1):1-18. PubMed ID: 27798112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interferon-γ induces leucine-rich repeat kinase LRRK2 via extracellular signal-regulated kinase ERK5 in macrophages.
    Kuss M; Adamopoulou E; Kahle PJ
    J Neurochem; 2014 Jun; 129(6):980-7. PubMed ID: 24479685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparative study of Lrrk2 function in primary neuronal cultures.
    Dächsel JC; Behrouz B; Yue M; Beevers JE; Melrose HL; Farrer MJ
    Parkinsonism Relat Disord; 2010 Dec; 16(10):650-5. PubMed ID: 20850369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification and characterization of a leucine-rich repeat kinase 2 (LRRK2) consensus phosphorylation motif.
    Pungaliya PP; Bai Y; Lipinski K; Anand VS; Sen S; Brown EL; Bates B; Reinhart PH; West AB; Hirst WD; Braithwaite SP
    PLoS One; 2010 Oct; 5(10):e13672. PubMed ID: 21060682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of chemicals to inhibit the kinase activity of leucine-rich repeat kinase 2 (LRRK2), a Parkinson's disease-associated protein.
    Yun H; Heo HY; Kim HH; DooKim N; Seol W
    Bioorg Med Chem Lett; 2011 May; 21(10):2953-7. PubMed ID: 21474311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily.
    Stafa K; Tsika E; Moser R; Musso A; Glauser L; Jones A; Biskup S; Xiong Y; Bandopadhyay R; Dawson VL; Dawson TM; Moore DJ
    Hum Mol Genet; 2014 Apr; 23(8):2055-77. PubMed ID: 24282027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Leucine-rich repeat kinase 2 modulates retinoic acid-induced neuronal differentiation of murine embryonic stem cells.
    Schulz C; Paus M; Frey K; Schmid R; Kohl Z; Mennerich D; Winkler J; Gillardon F
    PLoS One; 2011; 6(6):e20820. PubMed ID: 21695257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: impairment of the kinase activity by Parkinson's disease-associated mutations.
    Ohta E; Kawakami F; Kubo M; Obata F
    FEBS Lett; 2011 Jul; 585(14):2165-70. PubMed ID: 21658387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. G2019S LRRK2 mutant fibroblasts from Parkinson's disease patients show increased sensitivity to neurotoxin 1-methyl-4-phenylpyridinium dependent of autophagy.
    Yakhine-Diop SM; Bravo-San Pedro JM; Gómez-Sánchez R; Pizarro-Estrella E; Rodríguez-Arribas M; Climent V; Aiastui A; López de Munain A; Fuentes JM; González-Polo RA
    Toxicology; 2014 Oct; 324():1-9. PubMed ID: 25017139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation.
    Su YC; Qi X
    Hum Mol Genet; 2013 Nov; 22(22):4545-61. PubMed ID: 23813973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Leucine-rich repeat kinase 2 modulates neuroinflammation and neurotoxicity in models of human immunodeficiency virus 1-associated neurocognitive disorders.
    Puccini JM; Marker DF; Fitzgerald T; Barbieri J; Kim CS; Miller-Rhodes P; Lu SM; Dewhurst S; Gelbard HA
    J Neurosci; 2015 Apr; 35(13):5271-83. PubMed ID: 25834052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation.
    Luzón-Toro B; Rubio de la Torre E; Delgado A; Pérez-Tur J; Hilfiker S
    Hum Mol Genet; 2007 Sep; 16(17):2031-9. PubMed ID: 17584768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phosphorylation of LRRK2: from kinase to substrate.
    Lobbestael E; Baekelandt V; Taymans JM
    Biochem Soc Trans; 2012 Oct; 40(5):1102-10. PubMed ID: 22988873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.